Combination therapy for chronic hepatitis c infection

Details Combination therapy for chronic hepatitis c infection Combination therapy for chronic hepatitis c infection

2000-05-02

2001-10-09

Carlson, Karen Cochrane (Department: 1653)

Drug, bio-affecting and body treating compositions

Lymphokine

Interferon

Reexamination Certificate

active

06299872

ABSTRACT:

Throughout this disclosure, various publications, patents and patent applications are referenced. The disclosures of these publications, patents and patent applications are herein incorporated by reference.
Chronic infection with hepatitis C virus is an insidious and slow-progressing disease having a significant impact on the quality of life. It can eventually result in cirrhosis of the liver, decompensated liver disease and/or hepatocelluar carcinoma.
Alpha interferon monotherapy is commonly used to treat chronic hepatitis C infection. However this treatment is not always effective and sometimes results in intolerable side effects related to the dosage and duration of therapy. Ribavirin has been proposed as a monotherapy treatment for chronic hepatitis C infection (Thomas et al. AASLD Abstracts, Hepatology Vol. 20, NO. 4, Pt 2, Number 440, 1994). However, this monotherapy treatment has usually been found relatively ineffective and has its own undesirable side effects.
Combination therapy of alpha interferon and ribavirin has been proposed (Lai, et al. Symposium to the 9th Biennial Scientific Meeting Asian Pacific Association for the Study of the Liver. 1994). Preliminary results suggest that the combination therapy may be more effective than either monotherapy. However at the proposed dosages, undesirable side effects have still been encountered.
There is a need for a method for treating chronic hepatitis C infection with a combination of alpha interferon and ribavirin in the substantial absence of side effects normally associated with either compound.
SUMMARY OF THE INVENTION
This invention may be summarized as a method for treating chronic hepatitis C infection in patients in need of such treating comprising administering an amount of alpha interferon in association with an amount of ribavirin effective to treat hepatitis C in the absence or substantial reduction of side effects associated with ribavirin and alpha interferon.


REFERENCES:
patent: Re. 29835 (1978-11-01), Witkowksi et al.
patent: 4211771 (1980-07-01), Witkowski et al.
patent: 4530901 (1985-07-01), Witkowski et al.
Bizollon et al., Benefit of the combination interferon (IFN)-ribavirin in the treatment of C viral reinfections following hepatic transplantation (HT), Revue Francaise de Castro-enterologie (1994) 30(297), Case No. ID0492.*
Brillanti et al., Gastroenterology (1994) 107:812-817.*
Carreno et al., J. Med. Virol. (1992) 37(3): 215-219.*
Drinkard et al., A Phase I trial of intensive concomitant chemoradiotherapy with cisplatin dose escalation in advanced malignancies of the chest (Meeting Abstract). 4th International Congress on Anti-Cancer Chemotherapy. Feb. 2-5, 1993, Paris, France.*
Kakumu et al., Gastroenterology (1993) 105:507-512.*
Lai et al., Treatment of Chronic Active Hepatitis C infection with a Combination of Roferon-A and Ribavirin (Meeting Abstract), 9th Biennial Scientific Meeting Asian Pacific Association for the Study of the Liver. Jan. 27, 1994, Kuala Lumpur, Malaysia.*
Nozaki et al., Rinsho Ketsueki. Japanese Journal of Clinical Hematology, (1993) 34(2):232-234.*
Cavaletto, L et al, Congress Proceedings from Ital. J. Gastrenterol., 25:443-68, Abstract at p. 452 (Venezia, Nov. 11-13, 1993).
Braconier et al, Scan. J. Infect. Dis. 27:325-9 (1995).
Schvarcz et al, J. Med. Virol. 46:43-47 (1995).
Brouwer et al, ISSN 21:Suppl 1, S1-S198 (1994).
The Merck Index, 11th Ed., Compound No. 8199.
Hepatology, vol. 20, No. 4, Pt. 2, Abstract Nos. 440 and 441.
Bisceglie et al, Hepatology 16:649-654 (1992).
Kakumu et al, Gastroenterology 105:507-512 (1993).
Marcellin et al, Baillere's Clin. Gastroenter. 8:233-253 (1994).
Brillanti et al, J. Hepatol. 18(Suppl. 1):S101 (Abstract No. T-69) (1993).
Sambataro, J. Hepatol. 18(Suppl. 1):S167 (Abstract No. T-377) (1993).
Wu et al, Antiviral Res. (Suppl. 1), Abstract No. 228 (1993).
Brillanti et al, Gastroenterology 107:812-817 (1994).
Brillanti et al, Hepatology 18:150A, Abstract No. 375 (1993).
Lai et al, Hepatology 18:93A, Abstract No. 146 (1993).
Chemello et al, J. Hepatol. 21 (Suppl. 1):S12 (Abstract No. GS 5/29) (1994).
Brouwer et al, J. Hepatol. 21 (Suppl. 1):S17 (Abstract No. WP2/08) (1994).
Package Insert for Intron A Interferon Alpha-2b Recombinant, 1992, Schering Corporation, Kenilworth, NJ.
Revue Francais de Castro-Enterologie, Apr. 1994, No. 297 (English Translation).

Affiliated with

Also associated with

Rating

Combination therapy for chronic hepatitis c infection does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Combination therapy for chronic hepatitis c infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Combination therapy for chronic hepatitis c infection will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2608886